Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEvans, Josieen_UK
dc.contributor.authorDonnan, Peter Ten_UK
dc.contributor.authorMorris, Andrew Den_UK
dc.description.abstractAim: To investigate whether patients require insulin as a result of poor adherence to oral hypoglycaemic agents (OHAs) in Type 2 diabetes. Methods: A diabetes information system and a database of drugs dispensed for the study period 1993-1996 were used in Tayside, Scotland (population 400 000). Patients aged over 34 years with Type 2 diabetes who had at least 6 months exclusive therapy with OHAs (sulphonylureas or metformin) prior to insulin treatment were identified. Intended duration of every OHA prescription was calculated from prescription details. Adherence was estimated by dividing total intended duration of OHA therapy by study time for each patient, and compared between those who did and did not convert to insulin. Results: There were 2537 patients on sulphonylureas (51% male, mean age 67 years). There was improved adherence in the 262 patients who commenced insulin, who had mean adherence of 88.3% (95% confidence interval (CI) 85.9-90.6%) compared with the remaining 2275 patients whose mean adherence was 87.4% (95% CI 86.7-88.2%). In a logistic regression analysis, the adjusted odds ratio (OR) for commencing insulin was 1.20 (95% CI 1.07-1.35) for a quartile increase in adherence. There were 1519 patients on metformin (49% male, mean age 64 years). Mean adherence was 79.7% (95% CI 76.4-83.1%) and 83.1% (95% CI 82.0-84.1%) in 169 patients who did and 1350 who did not commence insulin, respectively, with an adjusted OR for a quartile increase in adherence of 0.91 (95% CI 0.78-1.07). Conclusion: Despite suboptimal adherence to OHAs in Type 2 diabetes, this is not associated with subsequent requirement for insulin.en_UK
dc.publisherWiley-Blackwell for Diabetes UKen_UK
dc.relationEvans J, Donnan PT & Morris AD (2002) Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes. Diabetic Medicine, 19 (8), pp. 685-688.
dc.rightsThe publisher does not allow this work to be made publicly available in this Repository. Please use the Request a Copy feature at the foot of the Repository record to request a copy directly from the author. You can only request a copy if you wish to use this work for your own research or private study.en_UK
dc.subjectType 2 diabetesen_UK
dc.subjectOral hypoglycaemic agentsen_UK
dc.titleAdherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetesen_UK
dc.typeJournal Articleen_UK
dc.rights.embargoreason[Evans_2002_Adherence_to_oral_hypoglycaemic_agents.pdf] The publisher does not allow this work to be made publicly available in this Repository therefore there is an embargo on the full text of the work.en_UK
dc.citation.jtitleDiabetic Medicineen_UK
dc.type.statusVoR - Version of Recorden_UK
dc.contributor.affiliationHealth Sciences Research - Stirling - LEGACYen_UK
dc.contributor.affiliationUniversity of Dundeeen_UK
dc.contributor.affiliationUniversity of Dundeeen_UK
rioxxterms.typeJournal Article/Reviewen_UK
local.rioxx.authorEvans, Josie|0000-0001-6672-7876en_UK
local.rioxx.authorDonnan, Peter T|en_UK
local.rioxx.authorMorris, Andrew D|en_UK
local.rioxx.projectInternal Project|University of Stirling|
Appears in Collections:Faculty of Health Sciences and Sport Journal Articles

Files in This Item:
File Description SizeFormat 
Evans_2002_Adherence_to_oral_hypoglycaemic_agents.pdfFulltext - Published Version149.69 kBAdobe PDFUnder Permanent Embargo    Request a copy

This item is protected by original copyright

Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

The metadata of the records in the Repository are available under the CC0 public domain dedication: No Rights Reserved

If you believe that any material held in STORRE infringes copyright, please contact providing details and we will remove the Work from public display in STORRE and investigate your claim.